Fecal Immunochemical Test
Stool-based CRC screening most effective, cheapest method in low-adherence settings
Among populations with low adherence to colorectal cancer screening, annual fecal immunochemical testing was the cheapest and most effective noninvasive screening method, according to a study published in JAMA Network Open.
Can uptick in noninvasive CRC screening tests compete with standard colonoscopy?
Newly available noninvasive colorectal cancer tests have opened the doors to an uptick in screening, especially the first FDA-approved blood test. However, experts are unsure whether these will be as effective as colonoscopy.
Mailed FIT outreach increases CRC screening rates among diverse, low-income patients in US
A centralized colorectal cancer screening intervention boosted fecal immunochemical test completion, as well as follow-up colonoscopy, among average-risk individuals served by federally qualified health centers, according to research.
Risk for detecting CRC up to 13-times higher with fecal hemoglobin in prior negative FIT
The risk for detecting colorectal neoplasia at a subsequent screening increased by up to 13-fold relative to fecal hemoglobin concentrations in previous negative fecal immunochemical tests, according to research.
AI-assisted GI Genius ‘had no impact’ on serrated polyp detection in positive stool tests
PHILADELPHIA—An AI-assisted endoscopy module minorly improved adenoma detection during colonoscopy, but “had no impact” on serrated polyp detection in patients with positive stool tests, a presenter said at the ACG Annual Scientific Meeting.
Harms of FIT screening outweigh benefits for those with no history of fecal hemoglobin
Individuals with no detectable hemoglobin in previously negative fecal immunochemical tests had a “significantly higher” harm-to-benefit ratio for screening, with researchers suggesting less intensive screening for this population.
Similar rates of FIT completion support commencing colorectal cancer screening at age 45
Similar rates of fecal immunochemical test completion and colonoscopy yields among patients aged 45 to 49 vs. 50 years supported updated guidelines which recommend the initiation of colorectal cancer screening at an earlier age.
No reduction in gastric cancer incidence, mortality by adding H. pylori screening to FIT
An invitation to screen for Helicobacter pylori along with fecal immunochemical testing did not significantly reduce gastric cancer incidence or mortality over approximately 5 years vs. FIT alone, according to a study conducted in Taiwan.
CRC detected via screening associated with better disease-free, overall survival
Disease-free survival at 3 years was significantly higher among patients with screen-detected colorectal cancer vs. those with clinically detected CRC, according to a study conducted in the Netherlands.
FDA approves Cologuard Plus, Exact Sciences’ next generation stool test for CRC screening
The FDA approved Exact Sciences’ Cologuard Plus multitarget stool DNA test to screen adults aged 45 years or older at average risk for colorectal cancer, according to a company press release.